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oropharyngeal cancers under TNM8 guidelines: a two-tier
approach
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Max Robinson7, Navdeep S. Upile4, Rachel Brooker4, Mina Mesri8, Victoria Bingham1, Stephen McQuaid1,6, Terry Jones4,
Dennis J. McCance9, Manuel Salto-Tellez1,6, Simon S. McDade1 and Jacqueline A. James1,6
BACKGROUND: TNM8 staging for oropharyngeal squamous cell carcinomas (OPSCC) surrogates p16 immunohistochemistry for
HPV testing. Patients with p16+ OPSCC may lack HPV aetiology. Here, we evaluate the suitability of TNM8 staging for guiding
prognosis in such patients.
METHODS: HPV status was ascertained using p16 immunohistochemistry and high-risk HPV RNA and DNA in situ hybridisation.
Survival by stage in a cohort of OPSCC patients was evaluated using TNM7/TNM8 staging. Survival of p16+/HPV− patients was
compared to p16 status.
RESULTS: TNM8 staging was found to improve on TNM7 (log rank p= 0·0190 for TNM8 compared with p= 0·0530 for TNM7) in
p16+ patients. Patients who tested p16+ but were HPV− (n= 20) had signiﬁcantly reduced ﬁve-year survival (33%) compared to
p16+ patients (77%) but not p16− patients (35%). Cancer stage was reduced in 95% of p16+/HPV− patients despite having a
mortality rate twice (HR 2.66 [95% CI: 1.37–5.15]) that of p16+/HPV+ patients under new TNM8 staging criteria.
CONCLUSION: Given the signiﬁcantly poorer survival of p16+/HPV− OPSCCs, these data provide compelling evidence for use of an
HPV-speciﬁc test for staging classiﬁcation. This has particular relevance in light of potential treatment de-escalation that could
expose these patients to inappropriately reduced treatment intensity as treatment algorithms evolve.
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BACKGROUND
Transcriptionally active human papillomavirus (HPV) is the causal
agent in 13–60% of oropharyngeal squamous cell carcinoma
(OPSCC), with increasing incidence rates globally.1,2 HPV-related
(HPV+) OPSCC exhibits signiﬁcantly better prognosis than HPV
negative (HPV−) OPSCC, and the two tumour classiﬁcations
represent distinct molecular and clinical entities.3 Molecular
stratiﬁcation based on HPV status has recently been proposed
to improve clinical management. The American Joint Committee
on Cancer and the Union for International Cancer Control eighth
edition TNM staging guidelines (TNM8), effective January 2018,
recommend stratiﬁcation of OPSCC by HPV status to improve
staging.4,5 Due to insufﬁcient evidence supporting the clinical
need for a second line HPV test and for ease of clinical adoption,
use of p16 immunohistochemistry (IHC) alone as a surrogate
marker of HPV status has been recommended.6,7 p16 IHC is a
highly sensitive test surrogate for transcriptionally active HPV+
OPSCC; however, recent analyses have identiﬁed that as many as
20% of p16+ OPSCC patients may lack transcriptionally active
HPV with potential relevance to clinical outcomes.8–11 A recent
meta-analysis for head and neck cancers determined incidence
was approximately 6.7%.3 Hence, the United Kingdom (UK) Royal
College of Pathologists recommend use of a second line in situ
hybridisation test (ISH) for conﬁrmation of HPV status in p16
positive (p16+) tumours.12
Despite early indications of improved outcomes, current clinical
practice still dictates that all OPSCC patients are managed based
on stage and other clinical parameters.13 At present, patients with
OPSCC are only stratiﬁed by HPV status if they are enrolled in a
clinical trial evaluating de-intensiﬁcation of conventional treat-
ment modalities or new agents.13 The outcomes of ongoing
clinical trials for de-escalation of treatment based on p16 and/or
an ISH test (to conﬁrm HPV status) will make accurate classiﬁcation
and staging of patients increasingly important to ensure appro-
priate clinical management and prognostic predictions.11 The new
TNM8 staging guidelines, reduces stage allocation of HPV+
tumours by using p16 IHC alone and has set the precedent for
stratiﬁcation of OPSCC. This has been reﬂected in the most recent
www.nature.com/bjc
Received: 20 November 2018 Revised: 6 February 2019 Accepted: 6 February 2019
1Centre for Cell Research and Cell Biology, Queen’s University Belfast, Belfast, Northern Ireland, UK; 2Northern Ireland Cancer Registry, Belfast, Northern Ireland, UK; 3Centre for
Public Health, Queen’s University Belfast, Belfast, Northern Ireland, UK; 4Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, England, UK;
5Pﬁzer Oncology, Walton Oaks, England, UK; 6Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK; 7Centre for Oral Health Research, Newcastle University, England,
UK; 8Aintree University Hospital NHS Foundation Trust, Liverpool, England, UK and 9Department of Pathology, University of New Mexico Medical School, Albuquerque,
NM 87131, USA
Correspondence: Jacqueline A. James (j.james@qub.ac.uk)
© The Author(s) 2019 Published by Springer Nature on behalf of Cancer Research UK
recommendations on HPV testing guidelines published by the
College of American Pathologists.6
The aim of this study was to assess the prognostic relevance
of p16 positivity with and without transcriptionally active HPV in
a large, non-biased, combined UK cohort of OPSCC patients.
Three independent cohorts with similar baseline characteristics
were combined to evaluate the staging capacity of TNM8
for p16+ patients and to assess the impact of TNM8 staging in
p16+/HPV− patients.
MATERIALS AND METHODS
Patients
All consecutive OPSCCs diagnosed in Northern Ireland from 2000
to 2011 were included under ethical approval from the Northern
Ireland Biobank (NIB 11/0001). Two distinct OPSCC cohorts
diagnosed within the Liverpool Head and Neck Oncology Service
from 1998 to 2009 and 2002 to 2011, respectively, were accessed
under prior ethical approval (South Sefton Research Ethic
Committee, EC·47·01–6; North West Five Research Ethics Commit-
tee, EC·09·H1010·5, REC 11/NQ/0452 and REC 16/LO/1726). Clinical
data were retrieved from individual patient electronic clinical
records. Data recorded for each cohort included sex, age, tumour
stage, nodal status, distant metastases, treatment received,
smoking status, alcohol history, date of diagnosis and death.
Overall survival was deﬁned as the time from diagnosis until
time of death as recorded on the death certiﬁcate. Data were
right censored for patients still alive using the following censor
dates (Northern Ireland cohort: 05/12/2016, Liverpool cohort one:
24/11/2017, cohort two: 26/12/2017). Clinicians were unaware of
HPV status at the time of treatment for patients in the cohort.
Treatment decisions were made in accordance with contempora-
neous UK national guidelines.
Formalin ﬁxed parafﬁn embedded (FFPE) specimens (biopsies or
surgical resections) arising from the oropharynx were identiﬁed
from three independent UK OPSCC cohorts and used to construct
tissue microarrays (TMAs) wherever possible. Tumour site of origin
was determined in patients identiﬁed by clinical, pathological and
radiological review prior to inclusion in the study. Inclusion criteria
were based on conﬁrmed diagnosis of an untreated primary
OPSCC; here deﬁned as either base of tongue (C01), soft palate
(C05·1), uvula (C05·2) tonsils (C09), or oropharynx not otherwise
speciﬁed (C10·9).
Procedures
TMA sections were assessed for p16 IHC as previously described
using a Ventana Benchmark Autostainer with a commercial kit
(CINtec® p16 Histology); all assays were validated on full face
sections.2,14 For each patient, triplicate cores were indepen-
dently assessed by two investigators for all assays. Patients were
considered p16 positive by p16 IHC if there was strong and
diffuse nuclear and cytoplasmic staining in at least 70% of
tumour cells.15
Positive (either PPIB or UBC) and negative (DapB) reagent
controls were employed across TMAs and assessed prior to HPV
RNA-ISH detection in order to determine integrity of mRNA within
the TMA.16 Patient FFPE material positive by PPIB or UBC but
negative for DapB were considered suitable for analysis by the test
probe for HPV. For the Northern Ireland cohort, high-risk HPV RNA-
ISH was carried out in the Northern Ireland Molecular Pathology
Laboratory using RNAscope 2·0 manual assay with a pooled HPV
genotype detection kit (Probe-HPV-HR18 recognising HPV 16, 18,
26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82 E6/E7
mRNA, Advanced Cell Diagnostics). RNA-ISH for the Liverpool
cohort was carried out in the Newcastle upon Tyne Hospitals
National Health Service Foundation Trust using the RNAscope 2·0
manual assay with a pooled HPV genotype detection kit (pooled
HPV subtypes: Probe-HPV-HR7 recognising HPV 16, 18, 31, 33, 35,
52, and 58 E6/E7 mRNA, Advanced Cell Diagnostics). For both
cohorts, patients were considered HPV RNA-ISH positive if the
tumour tissue demonstrated brown reaction product speciﬁcally
localising within the malignant nuclei.
Owing to differences in HPV genotypes represented in the RNA-
ISH probes used in Northern Ireland and Liverpool, high-risk DNA-
ISH was utilised in order to prevent bias in patients who presented
with p16+/HPV− tumours. Patients were assessed for high-risk
HPV DNA-ISH as previously described using a Ventana Benchmark
Autostainer with a commercial kit (Inform HPV III family 16 probe
(B)-(recognising HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
and 66 subtypes).2,14 Patients were considered positive for HPV
DNA-ISH if tumour tissue demonstrated blue reaction product
speciﬁcally localising within the malignant nuclei.
Statistical analysis
Patients were initially staged according to TNM7 guidelines with
subsequent clinical restaging to TNM8 using p16 status. Cohort
baseline characteristics were compared between p16+ and p16−
OPSCC patients using Pearson’s chi-square test for independence.
Overall ﬁve-year survival analysis using the Kaplan–Meier
method was conducted. Survival curves were compared using
the log-rank test. The missing indicator method was used to
handle missing clinical data. Cox proportional-hazards models
were used to calculate hazard ratios (HR) and associated 95%
conﬁdence intervals (CI). Multivariable models were developed by
backwards selection of age, sex, smoking status, alcohol history
and treatment received.
The reporting standards of the current study fulﬁl recommen-
dations set by the STROBE statement for reporting of observa-
tional studies and the REMARK guidelines for tumour biomarker
prognostic studies.17–19
RESULTS
Clinical cohort
The three cohorts included 521 primary OPSCCs in previously
untreated patients for which HPV status was determined by p16
IHC and HPV RNA-ISH in 482 (93%) individuals. Of these, 446 (86%)
patients had complete treatment and staging information for
TNM7 and TNM8 and were therefore included in subsequent
analyses. The proportion of p16+/HPV+ patients in the Liverpool
cohorts was signiﬁcantly higher than observed in the Northern
Irish epidemiological cohort (47 and 66% vs. 37% in the Liverpool
A, Liverpool B and Northern Ireland cohorts, respectively), Table 1.
Interestingly, incidence of p16+/HPV− patients relative to p16
positivity within the Liverpool cohorts was lower than expected
when compared to the population based Northern Ireland cohort
(13 and 6% vs. 11% of p16+ cases were HPV− in the Liverpool A,
Liverpool B and Northern Ireland cohorts, respectively). In spite of
this, the three cohorts displayed similar baseline characteristics for
age, sex, TNM7 and TNM8 staging, supporting combination of the
cohorts for further analysis. As signiﬁcant differences were
identiﬁed between cohorts for smoking status, alcohol history,
treatment received and tumour site of origin (p < 0.0009) in
addition to p16/HPV status these were included in the multi-
variable survival analyses. Mean follow-up for the combined
cohort was 5.04 years (Range 0.01–25.06 years).
p16+/HPV− patients share similar baseline characteristics to
p16+/HPV+ patients but are more likely to be older and not
receive curative surgery
Approximately half (52%) of patients were p16 IHC positive. Of the
232 p16+ patients assessed, 20 (9%) did not test positive for HPV
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RNA. These 20 patients were also negative for HPV DNA-ISH
conﬁrming there was no bias due to differences in the type of RNA
ISH probe used between the two study sites. Incidence of
p16+/HPV+ and p16+/HPV− OPSCC was more common in males,
previous smokers and those presenting with advanced stage
according to TNM7 and stage II when adjusted using TNM8 (p <
0.05), Table 2. Patients with p16+/HPV+ OPSCC were more likely
to be under 60 years of age and to have received surgery with
curative intent than p16− or p16+/HPV− patients. p16+/HPV−
patients share similar baseline characteristics to p16+/HPV+
patients, including smoking habits and tumour site of origin, but
are more likely to be older and not receive curative surgery for
treatment.
Mortality of p16+/HPV− patients is similar to p16− patients but
TNM8 downstages 95% of p16+/HPV− patients to early stage
disease
Use of TNM8 staging improved upon TNM7 in all p16+ patients
within the combined cohort. TNM8 but not TNM7 showed
signiﬁcant differences in overall survival by stage; with only 60%
(95% CI: 47.96–75.93) of p16+ patients staged III/IV under TNM8
alive after ﬁve years compared to 67% (95% CI: 52.63–85.38) and
Table 1. Baseline characteristics of study patients, according to cohort
Study cohorts
Northern Ireland Liverpool A Liverpool B Combined p
(n= 232) (n= 66) (n= 148) (n= 446)
p16/HPV status – – – – <0.0001
p16− 137 (59%) 31 (47%) 44 (30%) 212 (48%) –
p16+/HPV+ 85 (37%) 31 (47%) 98 (66%) 214 (48%) –
p16+/HPV− 10 (4%) 4 (6%) 6 (4%) 20 (4%) –
Age (years) – – – – 0.4617
0–59 118 (51%) 39 (59%) 86 (58%) 243 (54%) –
60+ 114 (49%) 27 (41%) 62 (42%) 203 (46%) –
Sex – – – – 0.8385
Male 174 (75%) 51 (77%) 117 (79%) 342 (77%) –
Female 58 (25%) 15 (23%) 31 (21%) 104 (23%) –
Tumour site of origin – – – – 0.0009
Tonsil 98 (42%) 40 (61%) 68 (46%) 206 (46%) –
Base of tongue 60 (26%) 9 (14%) 56 (38%) 125 (28%) –
Oropharynx (unless otherwise speciﬁed) 74 (32%) 17 (26%) 24 (16%) 115 (26%) –
Smoking status – – – – <0.0001
Never 26 (11%) 11 (17%) 37 (25%) 74 (17%) –
Previous 57 (25%) 33 (50%) 62 (42%) 152 (34%) –
Current 94 (41%) 21 (32%) 47 (32%) 162 (36%) –
Missing 55 (24%) 1 (2%) 2 (1%) 58 (13%) –
Alcohol history – – – – <0.0001
No 36 (16%) 13 (20%) 107 (72%) 156 (35%) –
Yes 110 (47%) 51 (77%) 39 (26%) 200 (45%) –
Missing 86 (37%) 2 (3%) 2 (1%) 90 (20%) –
Surgery with curative intent – – – – 0.0004
Yes 139 (60%) 60 (91%) 96 (65%) 295 (66%) –
No 68 (29%) 6 (9%) 43 (29%) 117 (26%) –
No treatment/palliative 25 (11%) 0 (0%) 9 (6%) 34 (8%) –
TNM7 – – – – 0.7022
I 21 (9%) 4 (6%) 9 (6%) 34 (8%) –
II 33 (14%) 6 (9%) 12 (8%) 51 (11%) –
III 39 (17%) 11 (17%) 23 (16%) 73 (16%) –
IV 139 (60%) 45 (68%) 104 (70%) 288 (65%) –
TNM8 – – – – 0.0898
I 37 (16%) 10 (15%) 20 (14%) 67 (15%) –
II 85 (37%) 26 (39%) 76 (51%) 187 (42%) –
III 43 (19%) 9 (14%) 30 (20%) 82 (18%) –
IV 67 (29%) 21 (32%) 22 (15%) 110 (25%) –
Data is presented as number of patients (%). Differences in patient characteristics between the single study cohorts and the combined cohort were compared
using Fisher’s exact test for categorical variables
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78% (95% CI: 71.71–85.39) of stage I and II patients, respectively,
Fig. 1a, b. Restaging under TNM8 as p16+OPSCC reduced the
patient’s stage in 95% of patients with p16+/HPV− OPSCC. Patient
mortality of p16+/HPV− patients was similar to p16− patients;
with only 33% (95% CI: 17.00–63.30) and 35% (95% CI: 28.81–42.32)
of patients alive after ﬁve years, respectively, compared to 77%
(95% CI: 70.96–82.66) of patients with p16+/HPV+OPSCC, Fig. 2a.
HPV status was found to be an independent survival predictor
within p16+ OPSCCs, with HPV− patients having a two-fold
increased risk of death (HR .66 [95% CI: 1.37–5.15]) compared to
HPV+patients, Table 3. Prevalence of p16+/HPV+and p16+/HPV−
OPSCC within the population based Northern Ireland cohort was
found to be relatively consistent over the study period with an
average 40% of OPSCC being diagnosed as p16+ each year; 86%
of these were HPV+ and 14% HPV−, Fig. 2b. To summarise,
mortality of p16+/HPV− patients was similar to p16− patients but
TNM8 downstages 95% of p16+/HPV− patients to early stage
disease.
DISCUSSION
Inclusion of solitary p16 IHC testing with TNM8 improves
capability to appropriately stage OPSCC for prognostic stratiﬁca-
tion but it critically fails to recognise patients who lack HPV
aetiology and carry signiﬁcantly inferior clinical outcome. Inter-
rogation of HPV status using RNA-ISH within p16+ OPSCC
identiﬁed a subpopulation of p16+ patients who had a two-fold
increased risk of death following adjustment for potential
confounders. These p16+/HPV− patients were more similar to
patients with demonstrably HPV− disease and would stand to
beneﬁt from current standards of treatment intensity. Importantly,
when the newly proposed TNM8 staging guidelines were applied
we found that 95% of these p16+/HPV− patients would be down-
staged in circumstances where p16 IHC alone was used with no
additional conﬁrmatory ISH test. Due to selection bias in the
cohorts utilised only 9% of p16+ OPSCC patients were HPV− in
the combined cohort. However, when considered in the context of
a population-based cohort, this subpopulation was equivalent to
11% of p16+ OPSCC patients diagnosed in Northern Ireland over
a ten-year period. These ﬁndings carry signiﬁcant implications for
evolving treatment algorithms if HPV testing guidelines for patient
management follow precedent set by TNM8 for oropharyngeal
cancers; failure to conﬁrm true HPV status could result in
inappropriate de-escalation or sub-optimal therapy for these
p16+/HPV− patients.
TNM7 staging guidelines did not take into account prognostic
differences between HPV positive and negative cancers arising in
the oropharynx. Indeed, the use of TNM7 was found to be
insufﬁcient for staging patients with p16+OPSCC in our study, a
ﬁnding substantiated within the literature.20 TNM8 guidelines
were developed to take account of variations in prognosis within
OPSCC based on HPV status. Use of p16 IHC alone, as per
TNM8 staging guidelines, demonstrated improved prognosis in
our study but with overlap of stage I and II cancers as reported in
some but not all studies.21–25 As part of an ‘organ preservation’
strategy the primary treatment modality for the majority of
patients with OPSCC has been radiotherapy with and without
concurrent chemotherapy and as such TNM8 staging criteria has
been evaluated primarily in these patients.13,20 Notably our study
and other studies demonstrating overlap of stages I and II
included cohorts where the majority of patients received surgery
and where use of pathologic TNM8 staging was recommended
instead of clinical.23–26 Use of clinical TNM8 staging in retro-
spective cohorts of surgically managed patients may result in bias
producing the overlap of stage I and II patients.
Following the precedent set by the UICC, the College of
American Pathologists have updated their clinical recommenda-
tions for HPV testing and now advocate the use of p16 IHC as a
standalone test, citing insufﬁcient evidence of clinical need for a
second line test in oropharyngeal primaries.6 p16 IHC was chosen
for use in TNM8 as it is more cost effective and accessible to use
without specialist molecular tests however its use in isolation does
not meet the UK Royal College of Pathologists’ recommended
guidelines, under which our study is modelled.7,12 At present, HPV
assessment diagnostically for OPSCC is based on FFPE samples. As
the samples available were not fresh frozen, use of RT-PCR for HPV
detection could not be reliably used to conﬁrm HPV status in
p16+/HPV− samples. The HPV RNAscope assay has been
Table 2. Baseline characteristics of study patients in the combined
cohort, according to p16/HPV status
p16/HPV
status
p16− p16
+/HPV+
p16
+/HPV−
p
(n= 212) (n= 214) (n= 20)
Age (years) – – – <0.0001
0–59 94 (44%) 145 (68%) 4 (20%) –
60+ 118 (56%) 69 (32%) 16 (80%) –
Sex – – – 0.0478
Male 152 (72%) 175 (82%) 15 (75%) –
Female 60 (28%) 39 (18%) 5 (25%) –
Tumour site of origin – – – <0.0001
Tonsil 56 (26%) 141 (66%) 9 (45%) –
Base of tongue 66 (31%) 53 (25%) 6 (30%) –
Oropharynx (unless
otherwise speciﬁed)
90 (42%) 20 (9%) 5 (25%) –
Smoker status – – – <0.0001
Never 10 (5%) 62 (29%) 2 (10%) –
Previous 50 (24%) 94 (44%) 8 (40%) –
Current 118 (56%) 40 (19%) 4 (20%) –
Missing 34 (16%) 18 (8%) 6 (30%) –
Alcohol history – – – 0.0002
No 55 (26%) 96 (45%) 5 (25%) –
Yes 108 (51%) 85 (40%) 7 (35%) –
Missing 49 (23%) 33 (15%) 8 (40%) –
Surgery with curative
intent
– – – <0.0001
Yes 121 (57%) 162 (76%) 12 (60%) –
No 65 (31%) 47 (22%) 5 (25%) –
No treatment/
palliative
26 (12%) 5 (2%) 3 (15%) –
TNM7 – – – <0.0001
I 31 (15%) 2 (1%) 1 (5%) –
II 37 (17%) 12 (6%) 2 (10%) –
III 36 (17%) 35 (16%) 2 (10%) –
IV 108 (51%) 165 (77%) 15 (75%) –
TNM8 – – – <0.0001
I 31 (15%) 32 (15%) 4 (20%) –
II 37 (17%) 140 (65%) 10 (50%) –
III 36 (17%) 40 (19%) 6 (30%) –
IV 108 (51%) 2 (1%) 0 (0%) –
Data is presented as number of patients (%). Differences in patient
characteristics according to p16/HPV status were compared using Fisher’s
exact test for categorical variables
Recommendations for determining HPV status in patients with oropharyngeal. . .
S G Craig et al.
4
demonstrated to be both optimally sensitive and speciﬁc for HPV
detection in FFPE tissue but does not have fully regulatory
approval for clinical use.16,9,27 We thereby eliminated potential
bias in HPV RNA-ISH detection between Northern Ireland and
Liverpool samples by testing all patient FFPE material that were
not positive for p16 IHC and HPV RNA-ISH with clinically approved
HPV DNA-ISH testing for FFPE samples. This established if any HPV
DNA from 12 high-risk genotypes was present in the tumour
tissue. No patient who was p16+/HPV RNA− was found positive
for HPV DNA thereby eliminating any potential bias in our study
because of the probes utilised.
We found the strategy of using p16 IHC followed by HPV RNA-
ISH has allowed identiﬁcation of all clinically relevant incidences of
transcriptionally active HPV+ tumours within our cohort and is
supported by recent meta-analyses which have demonstrated that
a two tiered test is essential for a reliable diagnosis.28 The College
for American Pathologists ﬁnds use of p16 IHC in patients with
primary OPSCC to be sufﬁcient for molecular stratiﬁcation of HPV
in the head and neck.6 Interestingly, the majority of p16+/HPV+
and p16+/HPV− tumours in our study originated in either base of
tongue or tonsil, supporting a recent meta-analysis, but we found
the oropharyngeal sub-site did not confer survival advantage
when adjusted for covariates.29 These data demonstrate that p16
IHC appropriately classiﬁed 91% of HPV+ patients, a ﬁnding
substantiated by recent meta-analyses within the literature for
head and neck cancers.3 Critically, we ﬁnd that the resulting 9% of
patients who are p16+/HPV− are of increasing clinical importance
and concern as these patients have signiﬁcantly reduced survival
compared to p16+/HPV+ patients and would not beneﬁt from
TNM8 staging guidelines; as 95% of patients with p16+/HPV−
tumours were found to be down-staged when assessed using
clinical TNM8 as HPV+ OPSCC.
Based on the results of the current study we ﬁnd that ongoing
clinical trials for de-intensiﬁcation of treatment in OPSCC patients,
which utilise p16 IHC only to stratify patients, carry potential for
p16+/HPV− patients to receive sub-optimal treatment as treat-
ment algorithms evolve.30,31 These ﬁndings are supported in a
recent study of OPSCC and stage, which utilised HPV DNA-ISH and
p16 IHC.32,33 In recognising the importance of a second line test to
prevent sub-optimal treatment of transcriptionally inactive HPV
tumours we ﬁnd conﬁrmation of HPV status would result in more
appropriate prognostication of p16+/HPV− patients and a better
staging tool overall for OPSCC.
To conclude, our study provides compelling evidence that
lack of a standardised two-tiered HPV testing process, when
using p16 IHC will negatively affect the clinical management of
p16+/HPV− patients as treatment algorithms evolve. When p16
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IHC is utilised as a ﬁrst line-screening test, subsequent
conﬁrmation of HPV status based on deﬁnitive HPV detection
using ISH must follow.
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Ethical approval: The study was conducted according to the Good Clinical Practice
guidelines and the Declaration of Helsinki. Ethical approval for work in the Northern
Ireland OPSCC cohort was granted under the Northern Ireland Biobank (NIB 11/0001).
Table 3. Multivariable analysis of study patients in the combined cohort
Univariate p Multivariable p
Hazard ratio (95% CI) Hazard ratio (95% CI)
p16/HPV status
p16+/HPV+ Reference – Reference –
p16+/HPV− 4.40 (2.39–8.13) <0.0001 2.66 (1.37–5.15) 0.0037
p16− 3.86 (2.77–5.38) <0.0001 2.03 (1.27–3.26) 0.0033
Age (years)
0–59 Reference – Reference –
60 2.00 (1.51–2.67) <0.0001 1.48 (1.09–2.01) 0.0126
Sex
Male Reference – Reference –
Female 0.83 (0.59–1.18) 0.3030 0.73 (0.51–1.05) 0.0883
Tumour site of origin
Tonsil Reference – Reference –
Base of tongue 1.94 (1.39–2.72) 0.0001 1.08 (0.75–1.55) 0.6903
Oropharynx (unless otherwise speciﬁed) 1.76 (1.24–2.50) 0.0017 0.99 (0.66–1.47) 0.9568
Smoker status
Never Reference – Reference –
Previous 1.44 (0.83–2.51) 0.1970 1.04 (0.59–1.83) 0.9045
Current 3.27 (1.95–5.49) <0.0001 1.41 (0.80–2.49) 0.2358
Missing 3.79 (2.12–6.77) <0.0001 1.26 (0.60–2.64) 0.5359
Alcohol history
No Reference – Reference –
Yes 1.89 (0.85–1.66) 0.3103 0.96 (0.67–1.38) 0.8357
Missing 1.96 (1.34–2.86) 0.0005 1.56 (0.93–2.61) 0.0938
Surgery with curative intent
Yes Reference – Reference –
No 2.10 (1.53–2.87) <0.0001 1.71 (1.22–2.39) 0.0017
No treatment/palliative 7.72 (5.08–11.73) <0.0001 3.74 (2.35–5.95) <0.0001
TNM8
I Reference – Reference –
II 0.71 (0.44–1.15) 0.1680 0.97 (0.59–1.62) 0.9159
III 1.31 (0.79–2.18) 0.3020 1.23 (0.73–2.07) 0.4394
IV 3.26 (2.07–5.11) <0.0001 1.93 (1.18–3.17) 0.0093
Data are hazard ratios (95% CI) and corresponding p values. Models were mutually adjusted for each variable included in the table using pairwise comparison
for the reference category in each covariate
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The Two distinct OPSCC cohorts diagnosed within the Liverpool Head and Neck
Oncology Service from 1998 to 2009 and 2002 to 2011, respectively, were accessed
under prior ethical approval (South Sefton Research Ethic Committee, EC·47·01–6;
North West Five Research Ethics Committee, EC·09·H1010·5, REC 11/NQ/0452 and REC
16/LO/1726).
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional afﬁliations.
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